

# Drug Coverage Decision for B.C. PharmaCare

## About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

## Details of Drug Reviewed

Drug	
Brand Name	Mictoryl® and Mictoryl® Pediatric
Dosage Form(s)	propiverine 30 mg and 45 mg modified release capsules (adults) and 5 mg oral tablet (pediatric)
Manufacturer	Duchesnay Inc.
Submission Type	<b>New Submission</b>
Use Reviewed	Overactive Bladder (OAB)
Common Drug Review (CDR)	Yes, CDR recommended: <b>to Reimburse with clinical criteria and/or conditions</b> . Visit the CDR website for more details: <a href="http://www.cadth.ca/sites/default/files/cdr/complete/SR0504_complete_Mictoryl_Apr-21-17-e.pdf">www.cadth.ca/sites/default/files/cdr/complete/SR0504_complete_Mictoryl_Apr-21-17-e.pdf</a> .
Provincial Review	DBC now screens drug submissions under review by the CDR to determine whether or not a full DBC review is necessary, based on past DBC reviews and recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry's drug coverage decision will be based on the CDEC recommendation and an internal review only. The DBC screened propiverine on December 5, 2016. The DBC advised that because propiverine is similar to some of the other drugs used for the treatment of OAB, the Ministry may accept the CDEC's recommendation for propiverine.
Drug Coverage Decision	<b>Non-Benefit</b>
Date	March 20, 2018
Reason(s)	<p><b>Drug coverage decision is consistent with CDR recommendation.</b></p> <ul style="list-style-type: none"> <li>The drug demonstrated some advantage over placebo in adult and pediatric patient, but there was no direct comparison with oxybutynin immediate release tablets for adult patients or with oxybutynin syrup for pediatric patients.</li> <li>There was no evidence presented to assess the effectiveness of propiverine as a second-line treatment to other antimuscarinics including oxybutynin.</li> <li>The CDR recommended that the drug be listed for the treatment of OAB with a condition drug plan cost for propiverine should not exceed the drug plan cost of oxybutynin immediate release tablets for adult patients or oxybutynin syrup for pediatric patients. The pan-Canadian Pharmaceutical Alliance (pCPA) and Duchesnay Inc. engaged in price negotiations; however, an agreement between the two parties was not reached.</li> </ul>
Other Information	None

### The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.